Milestone Scientific Scales CompuFlo Platform with Reimbursement, Physician Adoption
Event summary
- Milestone Scientific expanded its CompuFlo Advisor Program to 180 epidural procedure feedback submissions by September 2026, with 99.3% of physicians reporting ease of use.
- Medicare reimbursement of $325 per procedure under CPT® Category III code 0777T is driving commercial focus in Novitas and First Coast jurisdictions.
- Commercial infrastructure now includes 3 medical sales professionals, 15 sales consultants, and 3 distribution partners, targeting interventional pain practices and hospitals.
- University of Texas study linked CompuFlo to a 91% reduction in complications during spinal cord stimulator implantation.
The big picture
Milestone Scientific is positioning CompuFlo as a repeat-use technology in pain management and neuromodulation, leveraging reimbursement pathways and physician advocacy to scale. The strategy aligns with broader industry trends toward value-based care and clinical evidence-driven adoption. Success hinges on converting physician experience into recurring revenue and expanding into international markets.
What we're watching
- Reimbursement Expansion
- Whether Milestone can secure additional Medicare and commercial payer coverage beyond current jurisdictions.
- Physician Adoption
- The pace at which the Advisor Program converts physician experience into repeat utilization and disposable revenue.
- Clinical Validation
- How ongoing studies, including the University of Minnesota evaluation, will support broader utilization across pain management and neuromodulation.
Related topics